Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis

Florian M Marx, Ted Cohen, Nicolas A Menzies, Joshua A Salomon, Grant Theron, Reza Yaesoubi

Summary

Background In settings of high tuberculosis incidence, previously treated individuals remain at high risk of recurrent tuberculosis and contribute substantially to overall disease burden. Whether tuberculosis case finding and preventive interventions among previously treated people are cost-effective has not been established. We aimed to estimate costs and health benefits of annual post-treatment follow-up examinations and secondary preventive therapy for tuberculosis in a tuberculosis-endemic setting.

Methods We developed a transmission-dynamic mathematical model and calibrated it to data from two high-incidence communities of approximately 40,000 people in suburban Cape Town, South Africa. We used the model to estimate overall cost and disability-adjusted life-years (DALYs) associated with annual follow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combination, among individuals completing tuberculosis treatment. We investigated scenarios under which these interventions were restricted to the first year after treatment completion, or extended indefinitely. For each intervention scenario, we projected health system costs and DALYs averted with respect to the current status quo of tuberculosis control. All estimates represent mean values derived from 1000 epidemic trajectories simulated over a 10-year period (2019–28), with 95% uncertainty intervals (UIs) calculated as the 2.5th and 97.5th percentile values.

Findings We estimated that a single follow-up examination at the end of the first year after treatment completion combined with 12 months of secondary IPT would avert 2472 DALYs (95% UI −888 to 7801) over a 10-year period and is expected to be cost-saving compared with current control efforts. Sustained annual follow-up and continuous secondary IPT beyond the first year after treatment would avert an additional 1179 DALYs (−1769 to 4377) over 10 years at an expected additional cost of US$18.2 per DALY averted. Strategies of follow-up without secondary IPT were dominated (ie, expected to result in lower health impact at higher costs) by strategies that included secondary IPT.

Interpretation In this high-incidence setting, post-treatment follow-up and secondary preventive therapy can accelerate declines in tuberculosis incidence and potentially save resources for tuberculosis control. Empirical trials to assess the feasibility of these interventions in settings most severely affected by tuberculosis are needed.

Introduction

Considerable effort will be required to accelerate declines in tuberculosis incidence and mortality worldwide and ensure progress towards the global tuberculosis elimination targets.1 Although estimates of tuberculosis incidence and mortality indicate declining trends in many high-burden countries over the past few years,2 progress remains slow in settings with the highest incidence. Additional interventions to interrupt transmission and prevent disease progression might be necessary to effectively reduce tuberculosis in these settings.

While population-level interventions such as intensified case finding and preventive treatment are costly and have not yielded anticipated benefits,4 novel approaches that focus on groups at the highest risk of tuberculosis could be attractive alternatives. Whether targeting tuberculosis control interventions towards high-risk groups will be effective at the population level will depend on whether these groups are identifiable and accessible, and on the extent to which these groups contribute to transmission of Mycobacterium tuberculosis and overall tuberculosis burden.

Individuals who have previously completed an episode of tuberculosis treatment remain at high risk of developing tuberculosis again.3 This risk is usually highest in the first year after treatment completion, where endogenous reactivation (relapse) is the main mechanism of disease recurrence.5 In settings with a high force of infection, persistently high rates of recurrent tuberculosis after the first year,6 commonly due to exogenous reinfection, have been observed, which suggests that previously treated people might be...
Research in context

Evidence before the study

High rates of recurrent tuberculosis after completion of standard antituberculosis treatment have been reported from several settings with high tuberculosis incidence. To our knowledge, no empirical studies have been done to measure the population-level effect of interventions that aim to prevent recurrent disease or more rapidly detect tuberculosis in previously treated people. In a modelling study of a South African community with high tuberculosis incidence, we projected that targeting active case finding and preventive therapy among individuals who had previously completed a course of tuberculosis treatment could accelerate reductions in tuberculosis incidence and mortality. However, whether such interventions would be cost-effective remains unaddressed.

To establish whether other population-based mathematical models have been employed to estimate the effect of tuberculosis interventions targeted to previously treated people, we updated an earlier PubMed search of relevant articles published in any language up to June 1, 2020, using the following search: (tuberculosis AND (recurrence OR relapse OR reinfection OR re-infection OR re-treatment OR previous treatment) AND (model* OR simulation)). We found no other modelling study has addressed the population-level effects and cost-effectiveness of interventions targeted to people previously treated for tuberculosis.

Added value of this study

We used a calibrated transmission-dynamic mathematical model of tuberculosis among treatment-naïve and treatment-experienced people in a high-incidence setting in suburban Cape Town, South Africa, to understand whether two targeted interventions—post-treatment follow-up examinations and secondary isoniazid preventive therapy (IPT)—among people who had completed tuberculosis treatment would be cost-effective if implemented alongside existing tuberculosis control efforts. We found that a strategy combining targeted follow-up examinations and secondary IPT for 1 year after treatment completion would both improve health (estimated as disability-adjusted life years [DALYs] averted) and reduce tuberculosis control costs. Compared with this strategy, annual follow-up with continuous secondary IPT is expected to cost an additional US$182 per DALY averted. Follow-up examination alone, whether limited to or extended beyond the first year after treatment was dominated (ie, expected to result in lower health impact at higher costs compared to the other strategies modelled). The comparative performance of these strategies in terms of cost and health benefits is expected to be maintained even at reduced uptake (50%) of or high dropout (25% per year) from the targeted interventions.

Implications of all the available evidence

This study shows that, in tuberculosis-endemic and HIV-endemic settings, former patients with tuberculosis constitute an important risk group that would derive substantial health benefits from targeted interventions, at comparatively low cost. Our results suggest that post-treatment follow-up and secondary preventive therapy offered to people who have completed tuberculosis treatment would be cost-effective and potentially cost-saving for tuberculosis control. Empirical trials of these targeted interventions are now needed to assess their feasibility and benefits in populations most severely affected by tuberculosis.

Methods

Modelling approach

We developed and calibrated a stochastic compartmental model of the tuberculosis and HIV epidemic in a high-incidence setting of approximately 40,000 residents of two adjacent communities in suburban Cape Town, South Africa (see appendix p 2 for details on the study setting). The transmission-dynamic model is an extension of a model that we previously used to explore the impact of targeted active case finding and secondary IPT after tuberculosis treatment completion in the same study setting. The tuberculosis component of the model follows the conventions of earlier models with additional structure to distinguish between individuals who have never been treated for tuberculosis (treatment naïve) and those who have previously been treated for tuberculosis (treatment experienced; figure 1). Model transitions are fully described in the appendix (pp 2–3). Briefly, treatment-naïve susceptible adults transition from the susceptible state to the latently infected state or directly into the infectious tuberculosis state after primary infection. If diagnosed, infectious adults move especially susceptible to tuberculosis. In these settings, tuberculosis among previously treated people contributes substantially to the overall incidence and prevalence of active tuberculosis. Using a mathematical model of tuberculosis and HIV in suburban Cape Town, South Africa, we projected that targeting tuberculosis case finding and secondary prevention to previously treated people could yield substantial population-level reductions in tuberculosis incidence and mortality. However, it is not yet clear whether these types of targeted intervention are cost-effective options for tuberculosis control in a high-incidence setting.

In this analysis, we estimated the cost-effectiveness of targeted tuberculosis control strategies to find and prevent tuberculosis among people who have previously completed tuberculosis treatment. We considered targeted active case finding, implemented as annual post-treatment follow-up examinations, alone and in combination with secondary isoniazid preventive therapy (IPT). We also examined how variations in uptake and duration of follow-up examinations and secondary IPT affect the cost-effectiveness of these interventions.
into one of two treatment compartments: incomplete or completed treatment. Adults in the incomplete treatment state move into a treatment-experienced latently infected state or, upon persistent disease, an infectious tuberculosis state. Infectious adults transit, after passive case detection, back into one of the two treatment compartments. Adults who complete their treatment are allocated to an intervention arm or non-intervention arm. In the non-intervention arm, the transitions are similar to those for adults in the incomplete treatment state, and infectious adults can once again be passively detected and transition into either of the treatment compartments. Similar transitions apply to adults in the intervention arm; however, an additional case-detection rate, incremental to passive case finding, is implemented to model case detection during post-treatment follow-up. Furthermore, we allow rates of relapse and disease progression following reinfection to differ from those in the non-intervention arm to account for the effect of secondary preventive therapy. Adults with completed...
treatment who drop out of the intervention arm move into the non-intervention arm, with its respective case-detection, relapse, and reinfection rates.

For the present study, we distinguish between individuals who completed their tuberculosis treatment within the past year and those who completed treatment more than 1 year ago. Our model includes substructure for people living with HIV, who represent an important high-risk group for tuberculosis. The HIV component of our model accounts for HIV infection, progression to a state of immunocompromised HIV infection, and antiretroviral treatment (ART; figure 1). The model also includes a subcomponent for children aged 0–14 years (appendix pp 2–3). A detailed description of our modelling approach, including model structure, parameterisation, implementation, model calibration, and parameter estimation, can be found in the appendix (pp 2–13).

Key model assumptions
We made the following six key model assumptions about differences between treatment-experienced and treatment-naive people. (1) Individuals who complete tuberculosis treatment revert to a latently infected stage that is distinct from latent infection among treatment-naive individuals. Subsequent tuberculosis is either due to endogenous reactivation (relapse) or exogenous reinfection. (2) We allow for a higher risk of tuberculosis reactivation in individuals who have completed tuberculosis treatment compared with those who are treatment naive and latently infected. We assumed that the rate of relapse after completion of tuberculosis treatment is highest in the first year and lower in subsequent years after treatment, consistent with observations from the study setting and a review of clinical trial data.

3 (Due to the uncertainty about the degree to which previous tuberculosis disease is associated with immunity, we allow for previously treated people, when reinfected, to be equally protected against tuberculosis compared with treatment-naive latently infected people, and up to twice as susceptible compared with previously uninfected, treatment-naive people. (4) We allow for treatment-experienced people with tuberculosis to be more infectious than treatment-naive people with tuberculosis, consistent with local tuberculosis prevalence survey data showing that people with previously treated tuberculosis were more likely to report cough and to be smear positive. (5) We allow for differential rates of passive tuberculosis case finding among individuals with and without history of tuberculosis treatment. (6) Among individuals with incomplete tuberculosis treatment, we assumed that between 0% and 20% remained infectious, effectively resulting in higher rates of tuberculosis after incomplete treatment, consistent with findings from the study setting.

Model initialisation and parameter estimation approach
We specified an initial population size of 32889 people (25903 adults and 10427 children aged 0–14 years), intended to reflect the population size in 1992 and informed by local census data and projections of population growth. Model simulations were initiated in 1992, allowing for a 10-year burn-in period before the availability of local data for calibration, which were obtained between Jan 1, 2002, and Dec 31, 2008 (with prevalence estimates for 2002 only). This calibration period was chosen because of the availability of high-quality data. Because the values of many parameters in tuberculosis and HIV co-epidemic models are not known with certainty, we adopted a Bayesian calibration approach to identify parameter sets that resulted in simulated trajectories with good fit to demographic, programmatic, and observational study data available for our setting (appendix pp 10–11). To implement this approach, we used a sampling-importance-resampling algorithm under which uniform prior distributions were specified for each parameter, and multiple parameter sets were then randomly and independently selected from these distributions (sampling). We measured the goodness of fit for 20000 simulated trajectories against the calibration targets (importance). The calibration targets were operationalised as the likelihood of observing the calibration data conditional on the simulated values. A subset of 1000 parameter sets was then resampled for final analysis with sampling probability proportional to goodness of fit (resampling). Additional details about the parameter estimation approach and posterior distributions of key model parameters are shown in the appendix (pp 10–13). Figure 2 shows the fit of simulated trajectories against the calibration targets.

Base-case and intervention scenarios
We defined a base-case scenario of the current status quo of tuberculosis control in the study setting. Under this base-case scenario, treatment-naive and treatment-experienced adults with infectious tuberculosis are passively detected and treated for tuberculosis with no additional interventions implemented. Rates of passive case detection were estimated through model calibration; percentages of patients completing tuberculosis treatment were informed by programmatic data from the local tuberculosis register.

We assumed that two targeted interventions—follow-up examinations and secondary IPT—were implemented complementary to routine tuberculosis services provided under the base-case scenario in the study setting. For follow-up examinations, we assumed that patients with tuberculosis who are completing tuberculosis treatment are requested to return to the clinic once at the end of every year to be re-evaluated for tuberculosis. At follow-up, individuals are asked to produce a single sputum sample for bacteriological testing (spontaneous or induced). We assumed that mycobacterial culture is used as the single diagnostic screening test, given the high false-positive rate of Xpert MTB/RIF in people with a recent history of tuberculosis treatment.
considerations about the use of the screening test are provided in the appendix (pp 14–16). We modelled the effect of follow-up examinations as an additional rate of case finding (figure 1). Follow-up thus leads to more rapid initiation of tuberculosis treatment and reductions in the average diagnostic delay and expected period of infectiousness. For secondary IPT, we assumed that patients who complete tuberculosis treatment are offered isoniazid (300 mg daily) as preventive therapy. We modelled the effect of preventive therapy by reducing the rate of tuberculosis reactivation and the risk of progression to disease following reinfection. A preventive

---

**Figure 2:** Overview of calibration targets and fitted model trajectories

Red dots denote the 12 calibration targets, with error bars representing 95% CIs where applicable; grey lines represent 250 simulated trajectories produced by the calibrated model; the simulated trajectories that fell outside of the feasible regions (shaded areas) were considered extremely unlikely and were eliminated by the calibration method. The interval between the dashed vertical lines shows the model calibration period (2002–08).
effect of 65% (uncertainty interval [UI] 45–85) was assumed, informed by two previous studies. These estimates consider the possibility that secondary IPT might be ineffective in a small fraction of individuals who acquired drug resistance during their first tuberculosis treatment episode.

The relative effect of preventive therapy was assumed to be independent of HIV infection, but the absolute rate and risk reduction associated with this intervention remains greater for those with HIV given their higher reactivation rate and risk of progression. We also assumed that the protective effect does not extend beyond the cessation of preventive therapy.

When modelling intervention scenarios, we considered a 2×2 factorial design of either annual follow-up examination alone or combined with secondary IPT and their intended duration after completion of treatment (restricted to the first year after treatment or unlimited; appendix p 20). We modelled the uptake of the interventions as a probability after tuberculosis treatment completion (figure 1). In our primary analysis, we assumed that 75% of patients with tuberculosis completing treatment would agree to receive the intervention. We allowed for dropout from the interventions by enabling transitions from the intervention into the non-intervention compartments at varying rates (figure 1). We assumed that, on average, 15% of people currently enrolled in the interventions drop out every year (resulting in an expected duration of preventive therapy of 6·6 years). Both uptake of and dropout from the interventions were varied in secondary analyses. Individuals who were re-treated for tuberculosis were able to re-enter the interventions upon treatment completion.

Cost-effectiveness analysis
We estimated the costs for the base-case and intervention scenarios in 2018 US dollars, adopting a South African health-care system perspective (table 1). Average costs reflect 2018 estimates for tuberculosis health-care and diagnostic services in Cape Town that were obtained through review of the published literature and the official price list of the National Health Laboratory Service, South Africa. Cost estimates from previous years were converted into US dollars (where applicable) and adjusted for inflation using an average annual South African gross domestic product deflator rate of 5·71%. Costs for basic tuberculosis services reflect resources for the interventions by enabling transitions from the intervention into the non-intervention compartments at varying rates (figure 1). We assumed that, on average, 15% of people currently enrolled in the interventions drop out every year (resulting in an expected duration of preventive therapy of 6–6 years). Both uptake of and dropout from the interventions were varied in secondary analyses. Individuals who were re-treated for tuberculosis were able to re-enter the interventions upon treatment completion.

Table 1: Parameters for costs and disability weights

| Costs* | Value | Source |
|--------|-------|--------|
| Standard diagnostic evaluation (passive case finding) | | |
| Clinic visit for initial diagnosis (excluding tests) | $14.36 | Sinanovic et al (2015) |
| Xpert MTB/RIF (treatment naive only) | $14.80 | NHLS state price list |
| Mycobacterium tuberculosis culture (treatment experienced only) | $7.58 | NHLS state price list |
| Drug-susceptibility testing | $14.99 | NHLS state price list |
| Smear microscopy | $1.34 | NHLS state price list |
| Chest x-ray | $23.84 (16.22–33.85) | Menzies et al (2012) |
| Tuberculosis or HIV treatment | | |
| Drug-susceptible tuberculosis, full course | $708.15 (477.30–939.00) | Vassal et al (2011), Pooran et al (2013) |
| Multidrug-resistant tuberculosis, full course | $544.86 (322.56–765.57) | Vassal et al (2011), Pooran et al (2013) |
| ART, per month | $151.98 (122.47–184.44) | Menzies et al (2012) |
| Post-treatment follow-up examination | | |
| Follow-up clinic visit | $6.46 | Sinanovic et al (2015) |
| Mycobacterium tuberculosis culture screening for tuberculosis | $7.58 | NHLS state price list |
| Secondary IPT | | |
| IPT including monthly outpatient follow-up, per year | $20.25 (31.97–34.11) | Kim et al (2018), Johnson et al (2018) |
| Management of drug-induced liver injury, per event | $35.86 (24.22–90.06) | Kim et al (2018) |
| 7-day hospitalisation costs per severe drug-induced liver injury event | $813.05 (334.60–886.48) | Kim et al (2018) |

| Disability weights | | |
| Latent tuberculosis infection | 0 | |
| Untreated active tuberculosis, HIV negative | 0.333 [0.224–0.454] | GBD 2016 |
| HIV positive, non-immunocompromised | 0.012 [0.006–0.023] | GBD 2016 |
| HIV positive, immunocompromised | 0.428 [0.274–0.582] | GBD 2016 |
| HIV positive, on ART | 0.078 [0.052–0.111] | GBD 2016 |

Data in parentheses are uncertainty intervals. Price estimates for diagnostic tests were obtained from the NHLS price list and do not contain uncertainty intervals. NHLS=National Health Laboratory Service. IPT=isoniazid preventive therapy. ART=antiretroviral treatment. GBD=Global Burden of Disease Study.*Published cost estimates were converted into US dollars and inflated to 2018 price levels.
standard tuberculosis diagnostic evaluation among individuals self-presenting to primary health care, HIV testing and ART, and tuberculosis treatment. Costs for annual follow-up examinations reflect those for follow-up visits to the local clinic and culture-based screening for active tuberculosis (table 1). Costs for secondary IPT reflect drug supply and dispensing during monthly follow-up visits as well as the evaluation and management of potential drug-induced toxicity events (table 1). We assumed that 3·0% (UI 0·2–15·0) of individuals enrolled in secondary IPT would experience drug-induced liver injury, of which 1·4% (0·005–2·5) would be severe events requiring hospitalisation, and of the latter 5·2% (0·01–10·0) would lead to death.28

We further assumed that 0–2% of individuals receiving secondary IPT acquire drug-resistant tuberculosis. As the number of individuals developing drug-resistant tuberculosis through this pathway is expected to be low, we assumed that preventive therapy would not have a meaningful impact on the prevalence of drug-resistant tuberculosis. Hence, our model does not explicitly describe the dynamics of drug-resistant tuberculosis. However, we account for the treatment cost of individuals who acquired drug-resistant tuberculosis through secondary IPT (table 1).

We estimated disability-adjusted life-years (DALYs) as a measure of the health impact of the intervention scenarios (appendix p 18). Costs and health benefits were discounted at an annual rate of 3·0%. For each strategy considered here, we estimated the probability of it being the optimal strategy for a given cost-effectiveness threshold. At a cost-effectiveness threshold ω, a strategy is considered optimal if it results in the highest net monetary benefit, defined as ω×(DALYs averted by the strategy)−(incremental cost of the strategy).

As a sensitivity analysis, we calculated partial rank correlation coefficients to assess how sensitive our model outputs were to variation in input parameters (appendix p 19).

We followed the Consolidated Health Economic Evaluation Reporting Standards11 to report the results of our study. Model projections were made for the time period Jan 1, 2019 to Dec 31, 2028; estimates beyond would have come with considerable additional uncertainty for this relatively small study population. All estimates from the model are presented as the mean and 95% UIs (the 2·5th and 97·5th percentiles) of 1000 epidemic trajectories simulated over the 10-year period.

The model is coded in C# (release 8) and the analyses were done in Python (version 3.8).

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

Results
Under the base-case scenario, we estimated that in 2019, the incidence of tuberculosis in the population studied was 1624 cases (95% UI 1890–2687) per 100000 population. Tuberculosis incidence was 1218 cases (691–2098) per 100000 treatment-naive people and 7551 cases (3931–12531) per 100000 treatment-experienced people. Among incident tuberculosis cases who had previously completed tuberculosis treatment, 48% (32–62) were due to reactivation of tuberculosis (as opposed to reinfection). Identified posterior estimates for key parameters describing the natural history of tuberculosis among treatment-experienced and treatment-naive individuals stratified by HIV status are provided in the appendix (p 13).

Epidemiological projections of tuberculosis incidence under the base-case scenario and under each intervention scenario are shown in the appendix (p 20). We estimated an expected annual decline in tuberculosis incidence between 2019 and 2028 of 1·32% (95% UI −3·9 to 27·1) of tuberculosis deaths estimated to occur under the base-case scenario over the 10-year period (figure 3). Continuous use of annual follow-up and secondary IPT restricted to the first year, and 3·79% (1·73 to 5·62) under annual follow-up and continuous secondary IPT.

A combination of follow-up and secondary IPT limited to the first year is expected to avert 14·3% (95% UI 0·1 to 28·0) of incident tuberculosis cases and 12·2% (3·9 to 27·1) of tuberculosis deaths estimated to occur under the base-case scenario over the 10-year period (figure 3). Continuous use of annual follow-up and secondary IPT is expected to avert 20·4% (5·9 to 35·9) of incident tuberculosis cases and 18·2% (0·7 to 34·2) of deaths (figure 3).

We project that follow-up with secondary IPT limited to the first year after treatment would avert 2472 DALYs (95% UI −888 to 7801) over a 10-year period and be cost...
Table 2: Incremental costs, life-years saved, DALYs averted during 10 years, and ICERs for each of the intervention scenarios compared with the base case

| Intervention Scenario                        | Expected cost, thousands | Expected DALYs | Expected incremental cost, thousands* | Expected incremental DALYs averted* | ICER*  |
|---------------------------------------------|--------------------------|---------------|--------------------------------------|-------------------------------------|--------|
| First-year follow-up with 1-year of secondary IPT | $17,765 (10,419 to 27,039) | 29,476 (18,281 to 45,819) | -                                    | -                                   | Cost saving |
| Annual follow-up with continuous secondary IPT | $17,787 (10,419 to 27,129) | 28,296 (17,665 to 43,464) | $21 (-720 to 708) | 1179 (-1769 to 4377) | $18.2† |
| First-year follow-up                         | $17,894 (10,372 to 27,272) | 30,679 (18,760 to 48,808) | -                                    | -                                   | Dominated |
| Base case                                    | $17,926 (10,498 to 27,023) | 31,947 (18,909 to 51,604) | -                                    | -                                   | Dominated |
| Annual follow-up                             | $17,951 (10,516 to 27,168) | 30,299 (18,661 to 48,344) | -                                    | -                                   | Dominated |

Intervals in brackets denote 95% uncertainty intervals. Strategies are listed in increasing order of expected cost. ICERs are US$ per DALY averted. DALY = disability-adjusted life-year. ICER = incremental cost-effectiveness ratio. IPT = isoniazid preventive therapy. Estimates of incremental cost, incremental DALYs averted, and ICER are calculated only for non-dominated and non-cost-saving strategies. For annual follow-up with continuous secondary IPT, these estimates are calculated with respect to the first-year follow-up with 1 year of secondary IPT strategy as reference. The uncertainty interval of this ICER estimate cannot be calculated since the estimates of incremental costs and DALYs averted were negative for some model trajectories.

Table 2: Incremental costs, life-years saved, DALYs averted during 10 years, and ICERs for each of the intervention scenarios compared with the base case

Figure 4: Cost-effectiveness analysis of modelled interventions

(A) Expected incremental net monetary benefit of each strategy with respect to the base-case strategy (for a given cost-effectiveness threshold, the optimal strategy is the one with the highest expected incremental net monetary benefit). (B) Probability that a strategy results in the highest net monetary benefit for various cost-effectiveness thresholds. IPT = isoniazid preventive therapy. DALY = disability-adjusted life-year.

Discussion

In this study, we used a calibrated transmission-dynamic model of tuberculosis in a high-incidence setting to passive tuberculosis case detection among treatment-experienced people (incremental health impact only), the rate of relapse (first year: incremental health impact only), the relative susceptibility in HIV-negative people to reinfection after treatment, and the efficacy of secondary IPT (appendix p 19). Scenarios of lower uptake of the interventions (50% uptake among patients completing treatment vs 75% in the primary analysis) would result in lower health impact and reduce total costs estimated for the combined intervention of follow-up and secondary IPT; however, the combined intervention remained the optimal strategy (appendix p 22). Higher dropout rates (25% vs 15% per year in the primary analysis) would reduce impact and costs of the lifelong combined strategy but have little impact on the first-year combined strategy (appendix p 22).
estimate whether interventions targeted to previously treated people would be cost-effective for tuberculosis control. Our analysis suggests that a combined strategy of annual post-treatment follow-up examinations and secondary preventive therapy among individuals who completed their tuberculosis treatment has a high probability of being cost-saving for tuberculosis control if implemented in addition to current tuberculosis control efforts in this setting. With a cost-effectiveness threshold greater than $18·2 per DALY averted, sustained annual follow-up coupled with continuous secondary IPT is expected to be the optimal strategy.

While follow-up and secondary IPT limited to the first year after treatment is expected to minimise tuberculosis control costs and produce health gains relative to the status quo, sustained annual follow-up with continuous secondary IPT will result in the greatest health impact for a relatively low additional cost. Our projection that the combined intervention is cost-effective even when extended beyond the first year after treatment relates to the observation that, in this high-incidence setting, the risk of tuberculosis among those completing tuberculosis treatment remains elevated beyond the first year after treatment due to exogenous reinfection.6

To our knowledge, our study is the first to estimate the cost-effectiveness of interventions targeted to people with a history of previous tuberculosis treatment in a high-incidence setting. It extends findings of an earlier modelling study,12 in which we found that offering tuberculosis case finding and secondary IPT to people previously treated for tuberculosis could greatly accelerate declines in tuberculosis incidence and mortality in this setting. Both studies support the proposition that in settings with a high incidence of tuberculosis, previously treated people constitute an important group that might be especially attractive for targeted interventions given their high risk of recurrent tuberculosis and their probable role in transmission of M tuberculosis in the population.

Rigorous implementation of case finding and secondary preventive therapy is necessary to maximise population-level benefits of these targeted interventions.12 However, the results from our sensitivity analysis suggest that these interventions might be cost-effective even with lower uptake or retention, given that resources for individuals declining to participate or dropping out over time could be saved.

We note the following limitations to our study. Uncertainty around parameters of the natural history of tuberculosis, particularly those determining reinfection, disease progression, and mortality among previously treated individuals, as well as the quality of future case finding and tuberculosis care in our setting, leads to substantial uncertainty in the modelled outcomes. We aimed to reduce this uncertainty by calibrating our model to several targets based on observational data from our study setting including rates of recurrent tuberculosis due to reactivation (relapse) and reinfection as estimated in a large cohort analysis.7 While we allowed for differential susceptibility to tuberculosis among treatment-experienced and treatment-naive individuals, we did not explicitly model differential risk of exposure as a possible driver for recurrent disease.

As noted for our previous modelling study,12 this study was based on a high-incidence setting; therefore, estimates of population-level impact and cost-effectiveness might not be readily generalisable to other settings. We expect interventions among previously treated people to be less cost-effective in settings with lower tuberculosis incidence, and where a smaller proportion of the tuberculosis burden and transmission is attributable to people who have previously had tuberculosis. In particular, sustaining annual follow-up and continuous secondary IPT might be less attractive in lower-transmission settings, where reinfection after tuberculosis treatment might be less common.

We were unable to address several practical aspects that could represent challenges to successful implementation of follow-up examinations and secondary IPT. For example, given the low specificity of Xpert MTB/RIF for the diagnosis of recurrent tuberculosis in recently treated people,33,34 we considered the use of M tuberculosis culture as the screening test at follow-up. The expected duration between follow-up and confirmation of tuberculosis via culture result (usually 2–3 weeks) means that culture-positive individuals would have to be contacted to start their re-treatment. Initiation of presumptive re-treatment might be considered for individuals with a high clinical suspicion of recurrent tuberculosis. However, re-treatment would have to be discontinued in the event of a negative culture result. More complex screening algorithms—for example ruling in possible tuberculosis cases via Xpert MTB/RIF and ruling out via culture—might prove more practicable but come with increased costs.

There is uncertainty about the extent to which risk factors for isoniazid-induced toxicity events such as alcohol abuse, malnutrition, or a past history of toxicity16 might affect eligibility for preventive therapy after treatment, which would reduce uptake. Also, implementing these interventions requires that drug toxicity events be successfully detected and managed.

Finally, our study did not take into account potential additional disability related to the burden of post-tuberculosis lung disease. There is consistent evidence from studies for an association between repeated episodes of tuberculosis and deteriorating lung function or chronic lung disease.20 Preventing recurrent and first-time tuberculosis through targeted interventions might therefore produce additional health benefits not accounted for by our study.

In conclusion, our analysis suggests that interventions to detect and prevent recurrent tuberculosis among previously treated people would be cost-effective for...
tuberculosis control, and that practical efforts to assess their feasibility in high-incidence settings are warranted. Empirical trials of the feasibility, impact, and cost-effectiveness of follow-up examinations and secondary preventive therapy are needed to assess whether these targeted interventions could support tuberculosis control in populations most severely affected by tuberculosis. Efforts to better understand the factors that predispose patients with tuberculosis to a high risk of recurrent tuberculosis after completion of treatment could help to prioritise those who would benefit the most from interventions after completing treatment. Additional research is also needed to identify more sensitive, specific, and rapid diagnostic algorithms to detect recurrent tuberculosis. Other treatment regimens and strategies to prevent recurrent tuberculosis, including the recently recommended shorter preventive treatment regimens (eg, daily rifampicin for 4 months,5 weekly rifapentine/isoniazid for 3 months6), could be considered. Preventing and detecting recurrent tuberculosis should become part of an integrative post-tuberculosis care strategy that also addresses other long-term adverse health consequences including the burden of post-tuberculosis lung disease.

**Contributors**

FMM, TC, and RY conceived the study. FMM designed the study, developed the model structure, and collected the data. RY implemented the model and analysed the data. FMM wrote the first manuscript draft. All authors contributed to the study design and interpretation of the results. NAM and JAS advised the design, analysis, and interpretation of the health-economic analysis. NAM provided guidance on the Bayesian calibration approach. GT provided insights into alternative diagnostic algorithms relevant for the analysis. All authors revised the manuscript for important intellectual content and approved the final version.

**Declaration of interests**

We declare no competing interests.

**Acknowledgments**

We thank Karen Jennings and Judy Taylor (City Health, City of Cape Town, South Africa) for their support. This work was supported through a grant provided jointly by the Günther Labes Foundation and the Oskar Helene Heim Foundation to FMM, and grants provided by the National Institutes of Health (NIH) to TC, JAS, and NAM (R01 AI112438–01) and to RT (I01AI1179603). FMM was supported through the i3D Exchange program provided jointly by the Günther Labes Foundation and the Oskar Helene Heim Foundation. GT acknowledges funding from the EDCTP2 program (NIH award number R25GM102149 to J R C Pulliam and A Welte). GT acknowledges funding from the EDCTP2 program (NIH award number R25GM102149 to J R C Pulliam and A Welte). GT acknowledges funding from the EDCTP2 program (NIH award number R25GM102149 to J R C Pulliam and A Welte). GT acknowledges funding from the EDCTP2 program (NIH award number R25GM102149 to J R C Pulliam and A Welte).

**References**

1. Uplekar M, Wel D, Lonroth K, et al. WHO’s new end TB strategy. *Lancet* 2015; 385: 1799–801.
2. WHO. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
3. Ayles H, Moyoyo M, Du Toit E, et al. Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. *Lancet* 2013; 382: 1183–94.
4. Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. *N Engl J Med* 2014; 370: 301–10.
5. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. *Int J Tuberc Lung Dis* 2007; 11: 828–37.
6. Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. *Clin Infect Dis* 2016; 55: 1026–31.
7. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. *Am J Respir Crit Care Med* 2005; 171: 1430–35.
8. Glynn JR, Murray J, Bester A, Nelson G, Shwarzer S, Sonnenberg P. High rates of recurrence in HIV-infected and Hected patients with tuberculosis. *J Infect Dis* 2010; 201: 704–11.
9. den Boon S, van Lill SW, Borgdorff MW, et al. High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. *Emerg Infect Dis* 2007; 13: 1189–94.
10. Marx FM, Floyd S, Ayles H, Godfrey-Faussett P, Beyers N, Cohen T. High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. *Eur Respir J* 2016; 48: 1227–30.
11. Marx FM, Cohen T, Lombard C, et al. Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa. *Int J Tuberc Lung Dis* 2019; 23: 891–99.
12. Marx FM, Yaseoubi R, Menzies NA, et al. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. *Lancet Glob Health* 2018; 6: e426–35.
13. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. *Lancet* 1998; 352: 1886–91.
14. Cohen T, Dye C, Colijn C, Williams B, Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. *Expert Rev Respir Med* 2009; 3: 67–79.
15. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. *PLoS Med* 2012; 9: e1001347.
16. Yaseoubi R, Cohen T. Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics. *Proc Natl Acad Sci USA* 2013; 110: 9457–62.
17. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. *Int J Tuberc Lung Dis* 2010; 14: 241–42.
18. Marx FM, Dunbar R, Enarson DA, Beyers N. The rate of sputum smear-positive tuberculosis after treatment default in a high-burden setting: a retrospective cohort study. *PLoS One* 2012; 7: e45724.
19. Menzies NA, Soetemien DI, Pandya A, Kim JJ. Bayesian methods for calibrating health policy models: a tutorial. *Pharmacoconomics* 2017; 35: 613–24.
20. Theron G, Venter R, Calligaro G, et al. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? *Clin Infect Dis* 2016; 62: 995–1001.
21. Fitzgerald DW, Desvriaux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-infected individuals: a randomised trial. *Lancet* 2000; 356: 1470–74.
22. Churchyard GJ, Fielding KL, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? *Aids* 2003; 17: 2003–70.
23. Hermans SM, Grant AD, Chihota V, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. *BMC Med* 2016; 14: 65.
24. Sinanovic E, Ramma L, Vassall A, et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. *Int J Tuberc Lung Dis* 2015; 19: 172–78.
25. National Health Laboratory Service. State price list 2017. Johannesburg: National Health Laboratory Service, 2017.
26. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. *PLoS Med* 2011; 8: e1001120.
27. Pooran A, Pierson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? *PLoS One* 2013; 8: e54387.
28 Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. *Int J Tuberc Lung Dis* 2018; 22: 1435–42.

29 Johnson KT, Cluchyward GJ, Sohn H, Dowdy DW. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. *Clin Infect Dis* 2018; 67: 1072–78.

30 Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) disability weights. Seattle, WA: Institute for Health Metrics and Evaluation, 2017.

31 World Bank. Inflation, GDP deflator (annual %)—South Africa. https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG?locations=ZA (accessed Feb 20, 2020).

32 Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. *Value Health* 2013; 16: 231–50.

33 Mishra H, Reeve BWP, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. *Lancet Respir Med* 2020; 8: 368–82.

34 Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 2006; 174: 935–52.

35 Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. *Respiration* 2013; 86: 76–85.

36 Menzies D, Adjohuney M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. *N Engl J Med* 2018; 379: 440–53.

37 Sterling TR, Villarino ME, Borisov A5, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. *N Engl J Med* 2011; 365: 2155–66.